Barra A, Cordonnier C, Preziosi M P, Intrator L, Hessel L, Fritzell B, Preud'homme J L
Laboratory of Immunology and Immunopathology (Centre National de la Recherche Scientifique, Associated Unit 1172), University Hospital, Poitiers, France.
J Infect Dis. 1992 Nov;166(5):1021-8. doi: 10.1093/infdis/166.5.1021.
A randomized study was conducted in 40 allogeneic marrow recipients to compare the immunogenicity of two Haemophilus influenzae type b (Hib) vaccines (either the Hib capsular polysaccharide [Hib-CPS] or tetanus toxoid-conjugated Hib-CPS [Hib-CPS-T]). A second injection consisted of Hib-CPS-T. Before immunization, 3 patients had serum antibody levels > 1 microgram/mL. After the first injection, the response was better after Hib-CPS-T than after Hib-CPS but lower than in normal subjects; a number of patients lacked any IgG antibody response, especially after Hib-CPS. Of patients who received two injections of Hib-CPS-T, 85% achieved an antibody concentration > or = 1 microgram/mL. Hib-CPS-T induced a response in IgG2-deficient patients whereas Hib-CPS alone did not. IgG antibodies predominantly belonged to the IgG1 subclass. The antibody response was better in patients immunized late after graft. This study shows that Hib-CPS-T is more immunogenic than Hib-CPS in marrow recipients.
对40名同种异体骨髓移植受者进行了一项随机研究，以比较两种b型流感嗜血杆菌（Hib）疫苗（即Hib荚膜多糖[Hib-CPS]或破伤风类毒素结合的Hib-CPS[Hib-CPS-T]）的免疫原性。第二次注射为Hib-CPS-T。免疫前，3名患者的血清抗体水平>1微克/毫升。首次注射后，Hib-CPS-T后的反应比Hib-CPS后的反应更好，但低于正常受试者；一些患者缺乏任何IgG抗体反应，尤其是在接种Hib-CPS后。接受两次Hib-CPS-T注射的患者中，85%的抗体浓度达到或≥1微克/毫升。Hib-CPS-T在IgG2缺陷患者中诱导了反应，而单独的Hib-CPS则没有。IgG抗体主要属于IgG1亚类。移植后晚期免疫的患者抗体反应更好。这项研究表明，在骨髓移植受者中，Hib-CPS-T比Hib-CPS具有更强的免疫原性。
